Literature DB >> 18655752

Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins.

Sandrin C Bergheanu1, Theo Reijmers, Aeilko H Zwinderman, Ivana Bobeldijk, Raymond Ramaker, An-Ho Liem, Jan van der Greef, Thomas Hankemeier, J Wouter Jukema.   

Abstract

OBJECTIVE: Lipid profiling (lipidomics) may be useful in revealing detailed information with regard to the effects on lipid metabolism, the cardiovascular risk and to differentiate between therapies. The aims of the present study were to: (1) analyze in depth the lipid changes induced by rosuvastatin and atorvastatin at different dosages; (2) compare differences between the two drugs with respect to the lipid profile change; (3) relate the findings with meaningful pathological mechanisms of coronary artery disease. RESEARCH DESIGN AND METHODS: Liquid chromatography-mass spectrometry was applied to obtain the metabolite profiles of plasma samples taken from a prospectively defined subset (n=80) of participants in the RADAR study where a randomly assigned treatment with rosuvastatin or atorvastatin in increasing dosages was administered during an 18-week period.
RESULTS: A number of sphingomyelins (SPMs) and phosphatidylcholines (PCs) correlate with the different effects of the two statins on the LDL-C/HDL-C ratio. Rosuvastatin increased the plasma concentration of PCs after 6 and 18 weeks, while atorvastatin reduced the plasma concentrations of PCs at both timepoints and dosages (p<0.01 for between-treatment comparison). Both atorvastatin and rosuvastatin lowered plasma SPMs concentrations, but atorvastatin demonstrated a more pronounced effect with the highest dose (p=0.03). Rosuvastatin resulted in a significantly more effective lowering of the [SPMs/(SPMs + PCs)] ratio than atorvastatin at any dose/timepoint (p<0.05), a ratio reported to be of clinical importance in coronary artery disease.
CONCLUSIONS: The lipidomic technique has revealed that statins are different with regards to the effect on detailed lipid profile. The observed difference in lipids may be connected with different clinical outcomes as suggested by the [SPMs/(SPMs + PCs)] ratio.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18655752     DOI: 10.1185/03007990802321709

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  21 in total

Review 1.  Lipidomics as a tool for the study of lipoprotein metabolism.

Authors:  Anatol Kontush; M John Chapman
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

2.  Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families.

Authors:  Hemant Kulkarni; Peter J Meikle; Manju Mamtani; Jacquelyn M Weir; Marcio Almeida; Vincent Diego; Juan Manuel Peralta; Christopher K Barlow; Claire Bellis; Thomas D Dyer; Laura Almasy; Michael C Mahaney; Anthony G Comuzzie; Harald H H Göring; Joanne E Curran; John Blangero
Journal:  J Lipid Res       Date:  2014-03-13       Impact factor: 5.922

Review 3.  Lipid-lowering efficacy of rosuvastatin.

Authors:  Stephen P Adams; Sarpreet S Sekhon; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

Review 4.  Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection.

Authors:  Emily Bowman; Nicholas T Funderburg
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

5.  High-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapy.

Authors:  Stuart G Snowden; Dmitry Grapov; Magnus Settergren; Fabio Luiz D'Alexandri; Jesper Z Haeggström; Oliver Fiehn; Tuulia Hyötyläinen; Theresa L Pedersen; John W Newman; Matej Orešič; John Pernow; Craig E Wheelock
Journal:  Circ Cardiovasc Genet       Date:  2014-12

6.  Lipidomics: a tool for studies of atherosclerosis.

Authors:  Kim Ekroos; Minna Jänis; Kirill Tarasov; Reini Hurme; Reijo Laaksonen
Journal:  Curr Atheroscler Rep       Date:  2010-07       Impact factor: 5.113

7.  Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice.

Authors:  Chunxiu Hu; Heng Wei; Anita M van den Hoek; Mei Wang; Rob van der Heijden; Gerwin Spijksma; Theo H Reijmers; Jildau Bouwman; Suzan Wopereis; Louis M Havekes; Elwin Verheij; Thomas Hankemeier; Guowang Xu; Jan van der Greef
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

Review 8.  Lipidomics in vascular health: current perspectives.

Authors:  Genovefa Kolovou; Vana Kolovou; Sophie Mavrogeni
Journal:  Vasc Health Risk Manag       Date:  2015-06-12

9.  A lipidomic analysis approach to evaluate the response to cholesterol-lowering food intake.

Authors:  Ewa Szymańska; Ferdinand A van Dorsten; Jorne Troost; Iryna Paliukhovich; Ewoud J J van Velzen; Margriet M W B Hendriks; Elke A Trautwein; John P M van Duynhoven; Rob J Vreeken; Age K Smilde
Journal:  Metabolomics       Date:  2011-12-07       Impact factor: 4.290

Review 10.  Sphingomyelin in high-density lipoproteins: structural role and biological function.

Authors:  Roberto Martínez-Beamonte; Jose M Lou-Bonafonte; María V Martínez-Gracia; Jesús Osada
Journal:  Int J Mol Sci       Date:  2013-04-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.